爱尔兰爵士制药的defiteli在国内有吗？

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide () is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects.

Defiteli is a mixture of single-stranded oligonucleotides with antithrombotic and profibrinolytic properties, indicated for the treatment of severe veno-occlusive disease (VOD) in adults and children who have received chemotherapy and stem cell transplantation. It can increase fibrin lysis and modulate platelet activity to reduce procoagulant activity. It has not been reported to increase the risk of bleeding.  

Foreign researchers first reported the efficacy and prognosis of clinical application of defiteli in the United States. The results showed that the drug significantly improved the patient's prognosis and survival time. Over time, multiple studies have been reported to confirm the effectiveness of defibrotide sodium in HVOD, including a multi-center clinical study in Europe that showed that 55% of patients were in complete remission; 43% of patients were alive after 100 days of treatment.

Is Defiteli from Irish Jazz Pharmaceuticals available in the country?

The drug from Jazz Pharmaceuticals of Ireland has not yet been launched in China, so patients can only choose defiteli from Jazz Pharmaceuticals of Ireland, which is listed abroad.

Recommended related hot articles: /newsDetail/95236.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.